Skip to Main Content
Phase IIA

A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy

  • Study HIC#:2000030395
  • Last Updated:11/04/2021

The purpose of this study is to determine whether CVL-871 is safe and tolerable in patients with Dementia-Related Apathy and if CVL-871 shows changes in clinical measurements of apathy.

  • Age50 years - 85 years
  • GenderBoth
  • Start Date09/29/2021
  • End Date06/30/2022

Trial Purpose and Description

The purpose of this study is to determine whether CVL-871 is safe and tolerable in patients with Dementia-Related Apathy and if CVL-871 shows changes in clinical measurements of apathy.

Eligibility Criteria

Inclusion Criteria:

  • Meets diagnostic criteria for apathy in neurocognitive disorders clinically significant apathy
  • Mild to Moderate Dementia (AD, FTD, VAD, or DLB)

Exclusion Criteria:

  • Other significant psychiatric disorder(s)
  • Other neurological disorders (other than AD, FTD, VAD, or DLB)

Sub-Investigator

For more information about this study, contact:

Or contact the Help us Discover team on: